1-4 of 4
John Hewson
Close
Sort by
Journal Articles

FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death

Craig T. Wallington-Beddoe, BSc, MBBS, John Hewson, MBBS, Kenneth Francis Bradstock, MB, PhD, Linda J. Bendall, BSc, PhD
Journal: Blood
Blood (2010) 116 (21): 3260.
https://doi.org/10.1182/blood.V116.21.3260.3260
Published: 2010
Journal Articles

Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia

Roman Crazzolara, Adam Cisterne, Marilyn Thien, John Hewson, Rana Baraz, Kenneth F. Bradstock, Linda J. Bendall
Journal: Blood
Blood (2009) 113 (14): 3297–3306.
https://doi.org/10.1182/blood-2008-02-137752
Published: 2009
Includes: Supplemental data
Journal Articles

The mTOR Inhibitor RAD001 (Everolimus) Improves Survival in Preclinical Models of Primary Human ALL.

Roman Crazzolara, MD, Adam Cisterne, BSc, Marilyn Thien, Bsc, PhD, John Hewson, MD, Kenneth Francis Bradstock, MD, PhD, Linda J. Bendall, BSc, PhD
Journal: Blood
Blood (2007) 110 (11): 856.
https://doi.org/10.1182/blood.V110.11.856.856
Published: 2007
Journal Articles

CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice.

Julius Juarez, BSc, John Hewson, MD, Adam Cisterne, BSc, Rana Baraz, BSc, Kenneth F. Bradstock, MD, PhD, Linda J. Bendall, BSc PhD
Journal: Blood
Blood (2005) 106 (11): 4592.
https://doi.org/10.1182/blood.V106.11.4592.4592
Published: 2005